Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$1.63 ▲ +0.00
(0.00%)
MKT CAP: $1.9M • VOL: 11.8K
52W L $2 52W H $45
ROARABLE / RQD
D- • 37/100
PIOTROSKI
4 / 9
NXL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $301.6K | $168.7K | $110.7K |
| YoY Revenue Growth % | +78.8% | +52.3% | — |
| Gross Profit | $240.3K | $132.1K | — |
| Gross Margin % | 79.7% | 78.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$8.4M | -$7.8M | -$5.7M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$8.2M | -$7.6M | -$4.6M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.0M | -$3.9M | -$3.8M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$5.0M | -$3.9M | -$3.8M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $654.8K | $574.5K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $3.7M | $3.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NXL.